As Ampio Pharmaceuticals (AMPE) uses repositioned products to position itself for major growth, the management team is also being fortified to carry out the short- and long-term missions of the company.
Already boasting a team with decades of experience and expertise, the company announced on Monday the addition of Deborah Knobelman, Ph.D., as chief business officer, a position that will report directly to CEO Don Wingerter, according to Ampio's press release.
With multiple clinical trials coming to an end by the end of 2011, and with the commercialization of the sexual dysfunction drug Zertane seemingly imminent, major near-term growth could be in store for Ampio, and management believes that Knobelman bears the experience and skills necessary to maximize the value of the company's pipeline.
No comments:
Post a Comment